Michael Gotzmann

Ruhr University Bochum

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Andreas Mügge

BG University Hospital Bergmannsheil Bochum

Fabienne Kreimer

St. Josef-Hospital

Assem Aweimer

BG University Hospital Bergmannsheil Bochum

Aydan Ewers

BG University Hospital Bergmannsheil Bochum

Ibrahim El‐Battrawy

Ruhr University Bochum

Michael Lindstaedt

Aarhus University Hospital

Waldemar Bojara

Gemeinschaftsklinikum Mittelrhein

Alfried Germing

BG University Hospital Bergmannsheil Bochum

Fabian Schiedat

BG University Hospital Bergmannsheil Bochum

Leif Bösche

Ruhr University Bochum

Cooperative Institutions

Ruhr University Bochum

109

BG University Hospital Bergmannsheil Bochum

108

American College of Cardiology

Palo Alto Institute

St. Josef-Hospital

University Hospitals of the Ruhr-University of Bochum

University Hospital Münster

University of Münster

Heidelberg University

Charité - Universitätsmedizin Berlin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Full Issue PDF

JACC Basic to Translational Science (2018)

Douglas L. Mann St Louis L. Kristin Newby Brian H. Annex Nanette H. Bishopric

1) understand the different patterns of myocardial fibrosis and the degree of isoform-expression and phosphorylation changes in cardiomyocyte titin in the different hemodynamic subgroups of aortic stenosis; 2) examine the extent of myocardial remodeling in paradoxical aortic stenosis to help better understand the poor prognosis of these patients; and 3) review the current guidelines and management of severe aortic stenosis, including evaluation focused on hemodynamic subtypes.

10.1016/s2452-302x(18)30124-4

Cite

Citations (0)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure

Journal of Clinical Medicine (2023)

Michael Gotzmann Pauline Henk Ulrik Stervbo Arturo Blázquez-Navarro Andreas Mügge

Background: The inhibition of sodium-glucose co-transporter 2 (SGLT-2) has been shown to be beneficial in the treatment of diabetic and non-diabetic patients with heart failure. The underlying mechanisms are incompletely understood. The present prospective study investigates for the first time the effect of empagliflozin on various soluble markers of inflammation in patients with reduced ejection fraction (HFrEF). Methods: We included 50 inpatients with HFrEF and diabetes mellitus type 2. A total of 25 patients received a therapy with the SGLT-2-inhibitor empagliflozin in addition to standard medication; the other 25 patients did not receive empagliflozin and were considered the control group. Quality of life, functional status and soluble immunological parameters in serum were assessed at baseline and after 3 months. Results: The baseline characteristics of both groups revealed no significant differences. Patients on empagliflozin demonstrated a significant improvement in the Minnesota living with heart failure questionnaire (baseline 44.2 ± 20.2 vs. 24 ± 17.7; p < 0.001), in distance in the 6-min walk test (baseline 343 ± 145 m vs. 450 ± 115 m; p < 0.001) and in soluble interleukin-6 level (baseline 21.7 ± 21.8 pg/mL vs. 13.7 ± 15.8 pg/mL; p = 0.008). There was no significant change of these or other parameters in the control group (p > 0.05 each). Conclusions: The empagliflozin-induced improvement of quality of life and functional capacity in patients with HFrEF and type 2 diabetes mellitus is accompanied by a substantial reduction of interleukin-6 levels. Thus, anti-inflammatory effects may contribute to the benefits of SGLT-2-inhibitors in heart failure.

Empagliflozin

10.3390/jcm12134458

Cite

Citations (4)

Impact of lung diseases on morbidity and mortality after transcatheter aortic valve implantation: Insights from spirometry and body plethysmography

American Heart Journal (2015)

Michael Gotzmann Heiko Knoop Aydan Ewers Andreas Mügge Jörg Walther

10.1016/j.ahj.2015.07.011

Cite

Citations (20)

Supraventrikuläre Tachykardien und Vorhofflimmern

Springer eBooks (2024)

Michael Gotzmann Fabienne Kreimer

10.1007/978-3-662-70165-2_9

Cite

Citations (0)

Successful treatment of submassive pulmonary embolism with right ventricle strain using ultrasound-assisted thrombolysis with urokinase: a case report

Clinical Research in Cardiology (2023)

Hani Al‐Terki Michael Gotzmann Adnan Labedi Andreas Mügge

Strain (injury)

10.1007/s00392-023-02191-7

Cite

Citations (0)

Electrocardiography and Doppler Echocardiography for Risk Stratification in Patients With Chronic Heart Failure

ACC Current Journal Review (2005)

Christian Bruch Michael Gotzmann Joerg Stypmann

Risk Stratification

Affect

Earnings Management

Sample (material)

10.1016/j.accreview.2005.08.049

Cite

Citations (13)

Predicting risk of AF in ischaemic stroke using sinus rhythm ECG abnormalities: A meta-analysis

European Stroke Journal (2023)

Alexander Berry‐Noronha Luke Bonavia Duncan Wilson Antti Eranti Maria Uggen Rasmussen

Objective: To identify ECG changes in sinus rhythm that may be used to predict subsequent development of new AF. Method: We identified prospective and retrospective cohort or case control studies evaluating ECG patterns from a 12-lead ECG in sinus rhythm taken in hospital or community predicting subsequent development of new AF. For each identified ECG predictor, we then identify absolute event rates and pooled risk ratios (RR) using an aggregate level random effects meta-analysis. Results: We identified 609,496 patients from 22 studies. ECG patterns included P wave terminal force V1 (PTFV1), interatrial block (IAB) and advanced interatrial block (aIAB), abnormal P wave axis (aPWA), PR prolongation and atrial premature complexes (APCs). Pooled risk ratios reached significance for each of these; PTFV1 RR 1.48 (95% CI 1.04–2.10), IAB 2.54 (95% CI 1.64–3.93), aIAB 4.05 (95% CI 2.64–6.22), aPWA 1.89 (95% CI 1.25–2.85), PR prolongation 2.22 (95% CI 1.27–3.87) and APCs 3.71 (95% CI 2.23–6.16). Diabetes reduced the predictive value of PR prolongation. Conclusion: APC and aIAB were most predictive of AF, while IAB, PR prolongation, PTFV1 and aPWA were also significantly associated with development of AF. These support their use in a screening tool to identify at risk cohorts who may benefit from further investigation, or following stroke, with empirical anticoagulation.

Stroke

10.1177/23969873231172559

Cite

Citations (4)

Transcatheter Aortic Valve Replacement for Degenerative Bioprosthetic Surgical Valves

Circulation (2012)

Danny Dvir John G. Webb Stephen Brecker Sabine Bleiziffer David Hildick‐Smith

Background— Transcatheter aortic valve-in-valve implantation is an emerging therapeutic alternative for patients with a failed surgical bioprosthesis and may obviate the need for reoperation. We evaluated the clinical results of this technique using a large, worldwide registry. Methods and Results— The Global Valve-in-Valve Registry included 202 patients with degenerated bioprosthetic valves (aged 77.7±10.4 years; 52.5% men) from 38 cardiac centers. Bioprosthesis mode of failure was stenosis (n=85; 42%), regurgitation (n=68; 34%), or combined stenosis and regurgitation (n=49; 24%). Implanted devices included CoreValve (n=124) and Edwards SAPIEN (n=78). Procedural success was achieved in 93.1% of cases. Adverse procedural outcomes included initial device malposition in 15.3% of cases and ostial coronary obstruction in 3.5%. After the procedure, valve maximum/mean gradients were 28.4±14.1/15.9±8.6 mm Hg, and 95% of patients had ≤+1 degree of aortic regurgitation. At 30-day follow-up, all-cause mortality was 8.4%, and 84.1% of patients were at New York Heart Association functional class I/II. One-year follow-up was obtained in 87 patients, with 85.8% survival of treated patients. Conclusions— The valve-in-valve procedure is clinically effective in the vast majority of patients with degenerated bioprosthetic valves. Safety and efficacy concerns include device malposition, ostial coronary obstruction, and high gradients after the procedure.

Valve replacement

10.1161/circulationaha.112.104505

Cite

Citations (549)

Risk factors for non-benefit of implantable cardioverter defibrillator therapy

Scientific Reports (2025)

Fabienne Kreimer Marie Lewenhardt Ibrahim El‐Battrawy Arash Haghikia Michael Gotzmann

Abstract Studies have demonstrated overall prognostic benefits of ICD implantation in patients at increased risk of sudden cardiac death. However, results are inconsistent in certain subgroups. This study aims to evaluate the prognostic implications of comorbidities on ICD outcomes and compare trends in patient selection and outcomes over a decade-long inclusion period. This study analysed 422 patients undergoing ICD implantation between 2011 and 2020. The study endpoint “no-benefit” was characterized by death from any cause occurring without prior appropriate ICD therapy. Benefit of ICD implantation was defined as either receiving appropriate ICD therapy before death or surviving until the end of the observation period. During a mean follow-up of 4.2 ± 3.0 years, no-benefit of ICD implantation was observed in 84 patients (20%). Independent risk factors for no-benefit were age ≥ 68 years (HR 4.599, p < 0.001), anemia (HR 2.549, p < 0.001), peripheral artery disease (HR 2.066, p = 0.007), and chronic obstructive pulmonary disease (HR 1.939, p = 0.014). Subgroup analysis by age < 68 years and ≥ 68 years demonstrated that the risk of no-benefit increases with age and comorbidities. When comparing patients with ICD implantation in 2011–2015 with those in 2016–2020, there were no significant differences in one-, two- and three-year-no-benefit rates. Different comorbidities were associated with no-benefit in the early and late implantation groups. Risk factors such as older age and specific comorbidities are associated with a higher likelihood of no-benefit from ICD implantation. A careful patient selection and consideration of individual risk factors besides advanced age is important.

Clinical endpoint

10.1038/s41598-025-86022-x

Cite

Citations (0)

Second degree AV block and severely impaired contractility in cardiac myxedema: a case report

Thyroid Research (2015)

Apostolos Chatzitomaris Michael Scheeler Michael Gotzmann Roland Köditz Janice Schildroth

The heart is a major target organ for thyroid hormone action. Severe overt hypothyroidism can result in diastolic hypertension, lowered cardiac output, impaired left ventricular contractility and diastolic relaxation, pericardial effusion and bradycardia. However, the function of the atrial pacemaker is usually normal and the degree by which the heart rate slows down is often modest. Here we report the case of a 20 year old male Caucasian with severe overt hypothyroidism. He presented with syncopation due to second degree atrioventricular block type Mobitz 2 and heart failure with reduced ejection fraction (38 %). Laboratory testing revealed a severe overt hypothyroidism with markedly elevated TSH (>100 mIU/L) and reduced fT3 and fT4 levels. The condition was caused by hypothyroid Graves' disease (Graves' disease with Hashimoto component). Although magnetic resonance imaging of the heart demonstrated decreased cardiac contractility and pericardial effusion, suggesting peri-myocarditis, plasma levels for BNP and troponin I were low. A possible infectious cause was unlikely, since testing for cardiotropic viruses was negative. The patient was treated with intravenous levothyroxine and after peripheral euthyroidism had been achieved, left ventricular ejection fraction returned to normal and pericardial effusion dissolved. Additionally, bradycardiac episodes abated, although intermittent second degree AV block was still occasionally present during the night. In conclusion, overt hypothyroidism may be associated by cardiac myxedema affecting both electrophysiology and contractility, observations that underscore the necessity of thyroid testing in different phenotypes of heart failure.

Contractility

Myxedema

Atrioventricular block

10.1186/s13044-015-0018-2

Cite

Citations (8)